Latest Development Activity News

Rox Resources secures ASX waiver allowing a discounted Share Purchase Plan without shareholder approval, enabling eligible investors to buy shares at $0.35 each. This move streamlines capital raising while limiting dilution to around 2.5%.

Ionic Rare Earths Limited secured shareholder approval on all resolutions at its 2025 Annual General Meeting, including director election, share consolidation, and capital raising measures.

Elementos Limited has issued 17.5 million shares at 28 cents each as part of a strategic placement, with further shares planned for January 2026, positioning itself to capitalize on growing tin demand.

Aurum Resources has sold nearly 2.9 million Montage Gold shares for about A$23 million, doubling its initial investment and boosting its cash reserves to around A$40 million. This financial boost supports ongoing exploration and development at its key Côte d'Ivoire gold projects.

Rapid Critical Metals has completed the acquisition of the Webbs Consol Silver Project, consolidating a high-grade silver belt in New South Wales and positioning itself for accelerated growth.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Thunderbird Resources has completed its acquisition of LM2 Metals, gaining full ownership of the Springfield Gold Deposit in central NSW and issuing over 28 million shares as part of the deal.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

Ballymore Resources’ maiden reverse circulation drilling at the historic Torpy’s silver-lead-zinc mine reveals significant high-grade mineralisation, prompting a strategic pause for downhole EM surveys to refine exploration targets.

Redivium Limited is progressing recapitalisation efforts and revising its UK lithium-ion battery recycling project plans amid ongoing ASX suspension. The company is engaging Australian investors to support reinstatement and updating feasibility studies following site changes.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Australis Oil and Gas has struck two pivotal deals to advance its Tuscaloosa Marine Shale assets, securing a major US development partner and monetizing producing wells to strengthen its balance sheet.